Along with its CHF 23.3 million investment in 4D Lifetec AG, Xlife Sciences AG has brought an AI software developed specifically for 4D Lifetec to massively expand the functionality of its 4D Lifetest in digital health. In exchange, the investor acquired a 20% stake in the company.
The core mission of 4D Lifetec, empowering patients via early-stage cancer detection, is bolstered by their pioneering immuno-oncology biomarker, the 4D Lifetest. These tests, targeting early-stage cancer (I and II), promise proactive health safeguards and effective screening of patients. The easy-to-use IVD-certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set.
With the acquisition of Xlife Sciences portfolio company x-diagnostics GmbH in a share deal, 4D Lifetec is enhancing the capabilities of its 4D Lifetest with Artificial Intelligence (AI), which will redefine the landscape of cancer diagnosis. Wholly owned by Xlife Sciences, x-diagnostics was founded in 2021 in Zurich and develops products which use AI in the field of oncology, especially in the early detection of cancer cells. Integrating AI and digital health into diagnostics holds immense promise, thus positioning 4D Lifetec at the forefront of AI-backed diagnostics in the healthcare industry. The workflows are now being integrated and are planned to be available for the upcoming clinical evaluation in the US.
Positioned as an incubator and accelerator focused on the development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, Xlife Sciences additionally brings its invaluable expertise, a vast network, and access to cutting-edge AI solutions through its alliance with FUSE-AI GmbH. These technological advancements will empower 4D Lifetec to combine diverse data sources, including patient records, genetic data, and imaging, ensuring exhaustive decision-making support for oncologists. This will enhance precision in cancer diagnosis, ultimately boosting patient care standards and results.
Xlife Sciences has additionally made a direct cash investment of CHF 23.3 million in 4D Lifetec, establishing its position as a 20% shareholder in the Zug-based startup. With the support of Xlife Sciences, 4D Lifetec is also considering a possible IPO in the States. The fresh capital injection will thus be used to lay the groundwork for stock market readiness, facilitated by 4D Lifetec, already running an entity in the US.
(Press release/RAN)
Photo L-R: Giancarlo Rizzoli, CEO of 4D Lifetec, Arne Faisst, Chairman of 4D Lifetech and Oliver R Baumann, CEO of Xlife Sciences
Please login or sign up to comment.
Commenting guidelines